Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Phase 1

Recruiting

• Conditions: Stage IV Melanoma; Stage III Melanoma
• Interventions: Biological: TBX-3400

• Registration Number: NCT03385486
• Lead Sponsor: Taiga Biotechnologies, Inc.

Brief Summary

This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors.

The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity.

The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-12-03
• Study First Submitted QC: 2017-12-20
• Study First Posted: 2017-12-28
• Study Start: 2019-06-02
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-01
• Last Update Posted: 2022-05-03
• Primary Completion: 2023-02
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for participation in the study:

1. Histopathologically confirmed diagnosis of advanced, unresectable or metastatic malignant melanoma

2. Male or female patients age 18 or older

3. Previously treated with checkpoint inhibitor therapy either alone or in combination with either stable disease or progressive disease per RECIST version 1.1 (there is no minimum treatment duration for patients who have progressive disease while on checkpoint inhibitor therapy)

4. Measurable or evaluable disease by RECIST version 1.1

5. Capable of understanding and complying with protocol requirements

6. A life expectancy of greater than 24 weeks at Screening

7. ECOG Performance Status of 0 to 2

8. Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures

9. Adequate bone marrow, liver, and renal function as defined below:

   • hemoglobin ≥8.0 g/dL (transfusions allowed)
   • absolute neutrophil count ≥1500/µL
   • platelet count ≥100,000/µL (transfusions allowed)
   • alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of normal (ULN), or ≤5 times ULN for patients with known hepatic metastases
   • total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are present; patients with a known history of Gilbert's syndrome (≤3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
   • estimated glomerular filtration rate ≥50 mL/min/1.73 m^2 (using Cockcroft Gault formula)

Exclusion Criteria

Patients who meet any of the following criteria will not be eligible for participation in the study:

1. Pregnant or breast feeding
2. Developed immune-related toxicity while on prior checkpoint inhibitor therapy that has not yet returned to Grade 1 or better
3. Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted
4. Active, symptomatic central nervous system (CNS) metastases. Patients with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening
5. Any concurrent uncontrolled illness, including mental illness or substance abuse which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial
6. Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident
7. Women of childbearing potential who are unable or unwilling to use an acceptable method of contraception
8. Known infection with human immunodeficiency virus (HIV) that is not well controlled on anti-retroviral therapy as defined by HIV RNA more than 400 copies/mL or severely symptomatic
9. Presence of Hepatitis B and/or Hepatitis C active infection
10. Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
TBX-3400	TBX-3400	TBX-3400 by intravenous infusion

Primary Outcome Measures

Name	Time	Method
Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03	26 months	Adverse events from subject reporting

Secondary Outcome Measures

Name	Time	Method
Tumor responses as defined by irRECIST	26 months	Tumor measurements to assess disease state
Presence and/or concentration of anti TBX-3400 antibodies	26 months	Measure of immunogenicity of TBX-3400
Assessment of concentrations of certain chemokines, such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400	26 months	Preliminary efficacy assessment to measure activity of TBX-3400
Tumor responses as defined by RECIST version 1.1	26 months	Tumor measurements to assess disease state

Trial Locations

Locations (2)

University of Colorado Cancer Center; 🇺🇸 Denver, Colorado, United States

The Angeles Clinic and Research Institute; 🇺🇸 Los Angeles, California, United States